The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 13, 2024

Filed:

Apr. 09, 2021
Applicants:

Omeros Corporation, Seattle, WA (US);

University of Leicester, Leiester, GB;

Inventors:

Gregory A. Demopulos, Mercer Island, WA (US);

Thomas Dudler, Bellevue, WA (US);

Hans-Wilhelm Schwaeble, Mountsorrel, GB;

Assignees:

Omeros Corporation, Seattle, WA (US);

University of Leicester, Leicester, GB;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/40 (2006.01); A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61P 39/00 (2006.01); A61P 7/02 (2006.01); A01K 67/027 (2006.01); C12N 9/64 (2006.01); A61P 37/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A01K 67/0276 (2013.01); A61K 9/0019 (2013.01); A61P 7/02 (2018.01); A61P 39/00 (2018.01); C07K 16/40 (2013.01); C12N 9/6424 (2013.01); C12Y 304/21104 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0381 (2013.01); A01K 2267/0387 (2013.01); A61K 2039/505 (2013.01); A61P 37/06 (2018.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.


Find Patent Forward Citations

Loading…